North America Narcolepsy Drugs Market

North America Narcolepsy Drugs Market Size (2024 to 2029)

The size of the Narcolepsy Drugs Market in North America is estimated to grow at a promising rate from 2024 to 2029. Narcolepsy is a neurological disorder that decreases the ability to regulate sleep cycles.

Y-O-Y growth in the incidence of narcolepsy and other disorders associated with sleep and fulfillment of reimbursement schemes relevant to narcolepsy and bringing out awareness programs and services regarding the importance of early narcolepsy diagnosis are to propel the growth. Market key players, research and development activities headed by various academic and research institutes, and escalating demand for rare diseases medication from biopharmaceutical and biotechnology companies are likely to add fuel to the market. Around 135,000 to 200,000 citizens of the U.S. are diagnosed with narcolepsy, according to the National Institute of Neurological Disorders and Stroke in 2018. 1 in 2,000 people in the United States was diagnosed with narcolepsy in 2012. Growth in alcohol consumption, tobacco, smoking destroying the sleeping patterns and lifestyle changes in young singles, and augmenting stress levels are some factors stimulating the narcolepsy drug market in North America.

Less awareness about narcolepsy and significantly less per head healthcare expenses in the regional limits of middle and low-income countries is predicted to hinder the market growth during North America.

This research report on North America Narcolepsy Drugs Market has been segmented & sub-segmented into the following categories.

• By Type: Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Others
• By Indication: Daytime Extreme Sleepiness, Cataplexia, and Others
• By Country: The United States, Canada, and Rest of North America

Regional Analysis

North America is ruling the market and is accounted to hold remarkable growth in the global narcolepsy drugs market during the forecast period. This region is projected to maintain its dominance because having consciousness amid people, availability of outstanding healthcare amenities, and rising citizens in this region are predicted to stimulate market growth.

The USA holds a significant share in the market due to market leaders' presence and the presence of a stellar healthcare system. The United States is also the fastest-growing region due to increasing disposable income, growing awareness, and rising adoption rates. The United States is governing the Narcolepsy drugs market in North America due to different regulatory bodies guiding the production of pharmaceutical products. Governing bodies like US FDA motivates and upgrades the enhancement of treatment for rare diseases. North American countries' U.S. and Canada have favored the usage of generic drugs leading to an expanding number of international players to access the markets. Moreover, expanded research among the pharmaceutical and biotechnology industries is expected further to strengthen the market growth during the estimated period. An increase in the obese population, a firmly-developed healthcare domain, and substantial healthcare expenses are to surge the market. The existence of developed economies such as U.S and Canada market players like Mylan N.V., and Ligand Pharmaceuticals, and others in the regional limits boost the market growth of the Narcolepsy drugs market.

Some of the key players dominating the North America Narcolepsy Drugs market include Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.